Daré Bioscience, a biotech company focused on women's health, will hold a conference call and webcast on November 16, 2026, to discuss its financial results for the third quarter ended September 30, 2026, and provide a company update. The event will offer insights into the company's progress in advancing women's health solutions and its future plans. Investors can access the call via phone or webcast through the company’s website, with the webcast available for replay for 90 days.
Daré Bioscience's upcoming Q3 2026 financial results call coincides with a day where 83 of 150 Health-sector US stocks on Pluang rose while 55 fell. For readers following Health-sector stocks, here is Pluang's market snapshot as of Nov 10, 2026 19:42 WIB: WGS (GeneDx Holdings Corp) traded at USD 56.50 with a 14.03% decline and 100% buy order activity, BKD (Brookdale Senior Living Inc.) at USD 10.30 with a 10.63% rise but 100% sell order activity, and LQDA (Liquidia Corporation) at USD 49.97 with a 4.39% gain and predominantly sell orders.
project44 has partnered with Snowflake to enhance supply chain decision-making through Mo, an AI-powered supply chain analyst. Mo uses project44's extensive logistics data and Snowflake Cortex AI to provide accurate, consistent answers to complex sup...
H&R Block has launched the Emerald Advance Loan, a fixed-rate short-term loan up to $1,750 with a 35.90% APR, designed to help families cover year-end expenses without monthly payments. Borrowers repay the loan in full by March 31, 2027, with no impa...
Duke Robotics has entered a strategic collaboration with Greek security firm CRONOS to commercialize its Insulator Cleaning Drone (IC Drone) technology in Greece. This partnership leverages CRONOS's strong presence in Greece's critical infrastructure...
Alm. Brand A/S repurchased 1,369,397 shares between November 3 and 9, 2026, at an average price of DKK 17.46 per share. This is part of their announced buy-back program totaling up to DKK 593 million, aiming to reduce the number of outstanding shares...
Novartis has secured first place in the 2026 Access to Medicine Index, maintaining its lead since 2024 by excelling across all assessed technical areas, including governance, R&D, and product delivery. The company scored 3.86 out of 5 overall, with a...
